Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3513419 | 0.95 | MAPT (0.47) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL1337013 | 0.90 | MAPT (0.55) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL26270122 | 0.87 | GFER (0.52) | KDM4EMAPTGAAMAPK1HTT | |
| SCHEMBL27807002 | 0.87 | MAPT (0.46) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL3514309 | 0.86 | MAPT (0.47) | MAPTHTTRECQLHTR6ALDH1A1 | |
| SCHEMBL3512048 | 0.86 | PRKDC (0.51) | KDM4EMAPTGAAHTTALDH1A1 | |
| SCHEMBL3510961 | 0.85 | PDK2 (0.43) | MAPTMAPK1HTTALDH1A1GFER | |
| SCHEMBL28900107 | 0.85 | SIRT6 (0.61) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL3670487 | 0.85 | INSR (0.42) | KDM4EMAPTGAAPTK2BMAPK1 | |
| SCHEMBL3510237 | 0.82 | GPR119 (0.41) | KDM4EALDH1A1KMT2ARAB9AALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | claimed |
| CN-115916771-B | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2025-04-01 | — | — | CN | disclosed |
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117024379-B | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-117024379-A | Preparation method and application of 2-amino-4- (4-methyl-1-piperazine) benzoic acid tert-butyl ester | 济南国鼎医药科技有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023055952-A1 | NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2022-05-12 | — | — | US | disclosed |
| EP-2373626-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-11-18 | — | — | US | disclosed |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
| WO-2010069966-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| EP-2176231-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2010-04-21 | — | — | EP | disclosed |
| EP-2120932-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Nerviano Medical Sciences S.r.l. (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008074749-A9 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES SRL (IT) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009013126-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008074749-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292207-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, MAP3K3, MAP3K5 | KDM4E 953/4885MAPT 2440/4885GAA 1233/4885 |
| US-20100197665-A1 | INDAZOLE DERIVATIVES AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | MAP3K5, MAP3K19, MAP3K3 | KDM4E 832/4885MAPT 2569/4885GAA 1667/4885 |
| US-20220144813-A1 | SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K19, ABL1, MAP3K20 | KDM4E 1131/4885MAPT 2423/4885GAA 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.